Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
News-Medical.Net on MSN
Understanding the role of m6A methylation in acute lung injury pathogenesis
Acute lung injury (ALI) is a critical clinical condition characterized by diffuse inflammation of the lung parenchyma and ...
Savara Inc. (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and participate in ...
TipRanks on MSN
Savara Announces $75M Royalty Funding Agreement
Savara Inc. is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Their lead program, MOLBREEVI, is a recombinant human granulocyte-macrophage colony stimulating factor ...
Jefferies, Piper Sandler, and Guggenheim Securities acted as joint book-running managers for the offering. Oppenheimer & Co. acted as the lead manager, and Citizens Capital Markets and H.C. Wainwright ...
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has commenced an underwritten public offering of shares of its ...
Metabolic reprogramming in fibrotic lung diseases involves key metabolites like lactate, succinate, and 2-hydroxyglutarate, ...
9d
Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants
Jefferies, Piper Sandler, and Guggenheim Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as the lead manager, and Citizens Capital Markets and H.C.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback